The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma
- PMID: 12960594
- DOI: 10.1097/00006231-200309000-00003
The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma
Abstract
The therapeutic approach to recurrent well-differentiated thyroid cancer is based on the detection of active disease. While a measured increase of thyroglobulin level in an ablated patient is highly suggestive of recurrence, localization of the tumour is necessary for adequate treatment planning. A whole body scan with 131I yields false negative results in the presence of non-iodophyllic foci of disease. Hypermetabolic foci of differentiated thyroid carcinoma can be detected by gamma PET with 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG). This study retrospectively evaluated the therapeutic impact of the 18F-FDG scan in patients with suspected recurrent thyroid carcinoma in whom the iodine scan was negative. Twenty patients (five male, 15 female) aged 19-77 years, were suspected of having recurrent thyroid carcinoma due to elevated thyroglobulin levels and/or palpable neck findings. All whole body iodine scans obtained with diagnostic doses (74-148 MBq (2-4 mCi) of 131I), were reported normal, i.e., no iodophyllic foci were detected. Whole body gamma positron emission tomography (PET) imaging was performed in fasting patients following i.v. administration of 370 MBq (10 mCi) 18F-FDG, with a strict 1 h immobilization post-injection. Gamma PET results were validated either by anatomical imaging, repeat iodine scanning after administration of a therapeutic dose (at least 3,700 MBq (100 mCi) of 131I) or surgery. The impact of the FDG scan on patient management was evaluated by the referring physicians. Positive gamma PET results confirmed the presence of active disease in 14/15 patients. One false positive finding (fibrosis) and one false negative (carcinoid) were reported. Localization of hypermetabolic foci supported treatment decisions in 10 patients, and significantly altered therapeutic management in six others. Treatment was withheld in four patients with negative findings. The clinical impact of the scan in this patient group is similar to that reported in the literature and justifies its future implementation.
2003 Lippincott Williams & Wilkins
Similar articles
-
Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.J Nucl Med. 1999 Jun;40(6):986-92. J Nucl Med. 1999. PMID: 10452315
-
Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.Curr Med Imaging Rev. 2019;15(10):956-964. doi: 10.2174/1573405614666180718124739. Curr Med Imaging Rev. 2019. PMID: 32008523
-
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.J Clin Endocrinol Metab. 1999 Jul;84(7):2291-302. doi: 10.1210/jcem.84.7.5827. J Clin Endocrinol Metab. 1999. PMID: 10404792
-
Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.Semin Nucl Med. 2006 Jul;36(3):194-205. doi: 10.1053/j.semnuclmed.2006.03.002. Semin Nucl Med. 2006. PMID: 16762610 Review.
-
Positron emission imaging of head and neck cancer, including thyroid carcinoma.Semin Nucl Med. 2004 Jul;34(3):180-97. doi: 10.1053/j.semnuclmed.2004.03.004. Semin Nucl Med. 2004. PMID: 15202100 Review.
Cited by
-
The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma.World J Surg. 2008 May;32(5):708-15. doi: 10.1007/s00268-007-9361-3. World J Surg. 2008. PMID: 18204948
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical